These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 31848739)

  • 21. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
    BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer.
    Su GL; Wang YY; Wang JC; Liu H
    J Int Med Res; 2020 Jul; 48(7):300060520926408. PubMed ID: 32660291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.
    Bekir Hacioglu M; Kostek O; Kurt N; Kucukarda A; Gokyer A; Ustabasioglu FE; Karatas F; Tuncbilek N; Uzunoglu S; Bilici A; Cicin I; Erdogan B
    J BUON; 2019; 24(5):2198-2204. PubMed ID: 31786894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fruquintinib (Fruzaqla) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2024 Feb; 66(1696):e34-e35. PubMed ID: 38412270
    [No Abstract]   [Full Text] [Related]  

  • 28. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
    Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
    Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
    Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
    J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving survival in metastatic colorectal cancer through optimized patient selection.
    Bekaii-Saab TS; Barzi A; Cusnir M
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
    Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
    Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
    Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
    Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
    Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
    Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
    Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.
    Xue WS; Men SY; Liu W; Liu RH
    Medicine (Baltimore); 2018 Oct; 97(40):e12635. PubMed ID: 30290640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.